To confirm the anti-tumor effects of DOT1L inhibitors (SGC0946, EPZ-5676) in breast cancer, we used the MCF7 (ER-positive, HER2-negative) and SKBR3 (ER-negative, HER2-positive) cell lines for the analysis. Here, DOT1L is linked to neoplasm.